This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Can Elevance's (ELV) Q3 Earnings Beat on Carelon Strength?
by Zacks Equity Research
The third-quarter results of Elevance (ELV) are likely to reflect strong rate adjustments and membership growth in the Health Benefits business.
The Zacks Analyst Blog UnitedHealth, Chevron, AstraZeneca, Adobe and Pfizer
by Zacks Equity Research
UnitedHealth, Chevron, AstraZeneca, Adobe and Pfizer are part of the Zacks Analyst Blog.
Top Analyst Reports for UnitedHealth, Chevron & AstraZeneca
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Incorporated (UNH), Chevron Corporation (CVX) and AstraZeneca PLC (AZN).
Lexicon's (LXRX) Inpefa Gets Preferred Status at Express Scripts
by Zacks Equity Research
A pharmacy benefit manager decides to place Lexicon's (LXRX) heart failure drug as a preferred product on Medicare national formularies on Nov. 1. The stock jumped 12% post this announcement.
Will UnitedHealth's (UNH) UnitedHealthcare Unit Aid Q3 Earnings?
by Zacks Equity Research
UnitedHealth's (UNH) third-quarter results are expected to benefit from an increase in UnitedHealthcare's Community & State revenues as well as the number of people it served.
Can High Medical Costs Affect UnitedHealth (UNH) Q3 Earnings?
by Zacks Equity Research
UnitedHealth's (UNH) third-quarter results are likely to reflect growth in memberships and premium levels.
Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Astrazeneca (AZN) Gained But Lagged the Market Today
by Zacks Equity Research
Astrazeneca (AZN) concluded the recent trading session at $67.42, signifying a +0.81% move from its prior day's close.
Pharma Stock Roundup: LLY Offers to Buy POINT Biopharma & Other Updates
by Kinjel Shah
Eli Lilly (LLY) offers to buy POINT Biopharma for approximately $1.4 billion. Sanofi (SNY) partners with Teva for co-developing immunology candidate.
Sanofi (SNY) Stock Outperforms Industry YTD: What's Next?
by Zacks Equity Research
Continued strong sales of Dupixent, contributions from new product launches and positive pipeline progress are likely to keep Sanofi's (SNY) stock afloat.
Astrazeneca (AZN) Advances But Underperforms Market: Key Facts
by Zacks Equity Research
Astrazeneca (AZN) concluded the recent trading session at $66.62, signifying a +0.54% move from its prior day's close.
AstraZeneca (AZN) Settles Heartburn Drugs Lawsuits for $425M
by Zacks Equity Research
AstraZeneca (AZN) agrees to pay $425 million to settle lawsuits related to heartburn drugs, Nexium and Prilosec.
J&J's (JNJ) Rybrevant Combo Meets Primary Goal in NSCLC Study
by Zacks Equity Research
J&J (JNJ) meets the primary goal in the late-stage study of the combination therapy of Rybrevant and lazertinib against Tagrisso for EGFR-mutated first-line NSCLC.
AstraZeneca (AZN) Key Drugs to Aid Growth, Pipeline Strong
by Zacks Equity Research
AstraZeneca's (AZN) key drugs like Lynparza, Tagrisso, Fasenra and Farxiga should keep driving revenues. Its pipeline is strong, with several phase III data readouts lined up.
Is it Time to Buy Pfizer, Moderna, or AstraZeneca's Stock?
by Shaun Pruitt
Despite slowing COVID-19 vaccine sales these healthcare titans are trading at more reasonable valuations with a lot of the risk-to-reward being priced into their stocks considering their earnings potential.
Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Astrazeneca (AZN) closed at $67.42, marking a -0.77% move from the previous day.
Ionis (IONS) Inks New Deal With Roche to Develop Novel RNA Drugs
by Zacks Equity Research
Per the agreement, Ionis (IONS) will grant exclusive global rights to Roche to develop and market two novel RNA-therapeutics for Alzheimer's and Huntington's diseases.
Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) closed at $67.94 in the latest trading session, marking a -0.41% move from the prior day.
Ionis (IONS) Meets Rare Disease Drug Study Goal, Stock Up 8.5%
by Zacks Equity Research
Ionis (IONS) reports positive phase III study results, supporting the benefits of olezarsen to treat familial chylomicronemia syndrome (FCS), a rare genetic disorder.
AstraZeneca PLC (AZN) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Astrazeneca (AZN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
FDA Expands Lilly (LLY) Jardiance Label in Chronic Kidney Disease
by Zacks Equity Research
Following the latest approval, Lilly's (LLY) Jardiance can access a target market that affects more than 35 million adults in the United States.
AstraZeneca's (AZN) Dato-DXd Meets Goal in Breast Cancer Study
by Zacks Equity Research
AstraZeneca (AZN) announces positive results from the late-stage study evaluating its antibody-drug conjugate, Dato-DXd, in pre-treated patients with HR+/HER2- metastatic breast cancer.
CDC Recommends Pfizer's (PFE) RSV Jab to Protect Newborns
by Zacks Equity Research
Pfizer's (PFE) Abrysvo has been recommended by the CDC for preventing RSV in infants by immunizing pregnant women, during weeks 32-36 of pregnancy.
The Zacks Analyst Blog Highlights Pfizer, Merck and AstraZeneca
by Zacks Equity Research
Pfizer, Merck and AstraZeneca are part of the Zacks top Analyst Blog.
Pharma Stock Roundup: EU Nod to PFE's Litfulo, FDA Priority Tag to MRK Applications
by Kinjel Shah
The European Commission approves Pfizer's (PFE) Litfulo for severe alopecia areata. FDA gives priority tag to Merck's (MRK) supplemental applications for Welireg and Keytruda.